Ординатура / Офтальмология / Английские материалы / Oxford American Handbook of Ophthalmology_Tsai, Denniston, Murray_2011
.pdf
396 CHAPTER 12 Vitreoretinal
Box 12.3 Causes of macular holes
•Idiopathic
•Trauma
•CME
•Epiretinal membrane/vitreomacular traction syndrome
•Retinal detachment (rhegmatogenous)
•Laser injury
•Pathological myopia (with posterior staphyloma)
•Hypertension
•Diabetic retinopathy
LASER RETINOPEXY AND CRYOPEXY FOR RETINAL TEARS 397
Laser retinopexy and cryopexy for retinal tears
Laser retinopexy (slit lamp or indirect delivery systems)
Mechanism
Laser light is absorbed by target tissue, generating heat and causing local protein denaturation (photocoagulation) adhering the neural retina to the RPE. Green light is mainly absorbed by melanin and hemoglobin.
Indication
•Retinal break with risk of progression to rhegmatogenous retinal detachment (usually horseshoe tears) and without excessive subretinal fluid.
•Equatorial and postequatorial lesions can be reached with a slit-lamp delivery system; more anterior lesions require indirect laser with indentation or cryotherapy.
Method
•Consent: explain what the procedure does, the likely success rate (around 80%), and possible complications, including the need for retreatment (around 20%), and possible detachment despite treatment (9%, half of which are from a different break).
•Ensure maximal dilation (e.g., tropicamide 1% + phenylephrine 2.5%) and topical anesthesia (e.g., proparacaine 1%).
Slit lamp
•Set laser (varies according to model): commonly spot size of 500 μm, duration 0.1 sec, and low initial power, e.g., 100 mW.
•Position contact lens (usually a wide field lens e.g., transequator or the 3-mirror; require coupling agent).
•Focus and fire laser to generate 2–3 rings of confluent gray-white burns (adjust power appropriately).
Indirect ophthalmoscope
•Set laser (varies according to model): commonly duration 0.1 sec and low power, e.g., 100 mW.
•Insert speculum and coat cornea with hydroxypropylmethylcellulose or ensure regular irrigation to maintain clarity.
•While viewing with indirect ophthalmoscope, gently indent to clearly visualize lesion.
•Focus and fire laser to generate 2–3 rings of confluent gray-white burns (adjust power appropriately).
•Complications: failure resulting in retinal detachment, retinal/vitreous hemorrhage, epiretinal membrane formation, CME.
Cryopexy
Mechanism
Freezing causes local protein denaturation adhering the neural retina to the RPE.
398 CHAPTER 12 Vitreoretinal
Indication
•Retinal break with risk of progression to rhegmatogenous retinal detachment (usually horseshoe tears) and without excessive subretinal fluid.
•Cryotherapy is most suitable for pre-equatorial lesions. It has advantages over laser retinopexy when there is a small pupil or media opacity.
Method
•Consent: explain what the procedure does, the likely success rate, and possible complications, including treatment failure or need for retreatment, discomfort, inflammation, and retinal/choroidal detachment.
•Ensure maximal dilation (e.g., tropicamide 1% + phenylephrine 2.5%).
•Give local anesthesia (e.g., by subconjunctival or retrobulbar injection as this preserves mobility).
•Insert speculum and coat cornea with hydroxypropylmethylcellulose or ensure regular irrigation to maintain clarity.
•While viewing with indirect ophthalmoscope, gently indent with the cryoprobe to clearly visualize lesion.
•Surround the break with a single continuous ring of applications. The duration of each application should be just long enough for the retina to whiten, but the probe should not be removed until thawing has occurred.
•Post-procedure: consider mild topical steroid/antibiotic combination.
•Complications: inflammation, failure resulting in retinal detachment, retinal/vitreous hemorrhage, epiretinal membrane formation.
SCLERAL BUCKLING PROCEDURES 399
Scleral buckling procedures
Scleral buckling
Mechanism
It is suggested that the buckle closes the break by multiple mechanisms, including moving the RPE closer to the retina and moving the retina closer to the posterior vitreous cortex. It is postulated that these may reduce flow through the break (including the amount of fluid pumped through during eye movements) and relieve vitreous traction on flap tears.
Indications
•Most simple RRD and dialysis: procedure of choice in situations where there is no pre-existing PVD, since a vitrectomy would require the induction of a PVD during surgery (highly difficult maneuver).
•Segmental buckles: for single breaks or multiple breaks within 1 clockhour.
•Encircling bands: traditionally for extensive or multiple breaks or breaks in the presence of high-risk features (e.g., aphakia/pseudophakia, etc); however the majority of these would now have a vitrectomy.
Method
•Consent: explain what the operation does and the possible complications, including failure, diplopia, refractive change, inflammation, infection, hemorrhage, explant extrusion, and worsened vision.
Perform appropriate conjunctival peritomy
•Inspect sclera for thinning and anomalous vortex veins; place traction sutures around selected rectus muscles to assist positioning.
•Identify break by indirect ophthalmoscope and indentation using the cryoprobe (or one of a number of instruments specifically designed for this purpose).
•Perform cryopexy by surrounding break(s) with a continuous ring of applications. Each application should last just long enough for the retina to whiten; the probe should not be removed until thawing has occurred. Mark the external position of the break on the sclera using indentation and a marker pen.
•Select buckle size: this should cover double the width of the retinal tear; position so that it extends from ora serrata to cover the posterior lip of the break.
•Place partial-thickness 5–0 nonabsorbable sutures using a spatulated needle. These are usually mattress-type sutures and are placed at least 1 mm away from the buckle on either side. Wider separation of sutures may result in a higher buckle. The number of sutures depends on the size of explant.
•Tighten sutures. Tighter sutures results in a higher buckle.
•Confirm buckle position is correct and that arterial perfusion of the optic nerve is unaffected.
•Close conjunctiva (e.g., with 7–0 absorbable suture).
400 CHAPTER 12 Vitreoretinal
Complications
•Intraoperative: scleral perforation, subretinal fluid (SRF) drainage problems (retinal incarceration, choroidal/subretinal hemorrhage).
•Postoperative: infection, glaucoma, extrusion, choroidal effusion/ detachment, epiretinal membrane, CME, diplopia, refractive change, diplopia.
Prognosis
Anatomical success >90%, but only around 50% achieve a VA of 20/50 (macula-on detachments).
Options
Choice of buckle
Table 12.15 Buckle options
Material |
Solid silicone rubber vs. Silicone sponge |
Orientation |
Segmental vs. encircling |
Size |
Wide range available (and can be cut to size) |
|
|
Drainage procedures
Trans-scleral drainage of subretinal fluid with a 27–30 gauge needle is possible but is generally not necessary. This is sometimes combined with the injection of intravitreal air in the DACE (drain-air-cryotherapy-explant) procedure.
VITRECTOMY: OUTLINE 401
Vitrectomy: outline
Vitrectomy
Mechanism
Vitrectomy removes dynamic tractional forces exerted on the retina; static tractional forces arising from membranes/fibrovascular proliferation can be removed at the same time. Vitrectomy also allows access to the retina to permit drainage of subretinal fluid and insertion of tamponade agents.
Indications
Retinal detachments
•RRD: traditionally reserved for those with posterior retinal breaks, giant retinal tears, proliferative vitreoretinopathy, or media opacity; now usage is widened to include most bullous detachments, and detachments associated with aphakia/pseuodophakia (or other higherrisk features).
•TRD.
Other
•Diagnostic: e.g., biopsy for endophthalmitis, lymphoma.
•Pharmacological: e.g., administration of antibiotics, steroids.
•Macular pathology: macular holes, epiretinal membranes.
•Trauma: e.g., removal of foreign body.
•Persistent media opacity: vitreous hemorrhage, inflammatory debris, floaters (severe).
•Complications of cataract surgery: dropped nucleus, dislocated IOL.
Method
•Consent: explain what the operation does, the presence of a postoperative gas bubble, the importance of posturing, and possible complications, including failure, inflammation, infection, hemorrhage, and worsened vision.
•Make 3 sclerostomies 4 mm (phakic) or 3.5 mm (aphakic/pseudophakic) behind the limbus, placed inferotemporally, superotemporaly, and superonasally.
•Secure the infusion cannula to the inferotemporal port. The infusion is used to both maintain the globe (thus permitting aspiration) and increase pressure if intraocular bleeding occurs.
•Insert the light-pipe and then the vitrector through the two superior ports under visualization (contact lens or indirect microscope system with inverter).
•Vitrectomy: of the posterior vitreous face and extending out to the periphery.
•Replace the infusion fluid with a tamponade agent (usually gas, sometimes silicone oil for complicated cases).
•Close the sclerostomies.
•Postoperative care: advise patient regarding posturing and warn against air travel until gas is resorbed.
402 CHAPTER 12 Vitreoretinal
Complications
•Intraoperative: retinal breaks (posterior, peripheral), choroidal hemorrhage.
•Postoperative: retinal breaks/RRD, cataract, glaucoma, inflammation, endophthalmitis (1/2000), hypotony, corneal decompensation, sympathetic ophthalmia (0.01% of routine vitrectomy).
•Tamponade gas-associated: iIOP, posterior subcapsular “feathering” of the lens, anterior IOL movement (if pseudophakic).
•Silicone oil-associated: iIOP, emulsified silicone oil (“inverse hypopyon”), adherence to silicone IOL, silicone oil keratopathy (if oil in AC), peri-oil fibrosis.
Prognosis
Anatomical success for simple RRD is >90%.
VITRECTOMY: HEAVY LIQUIDS AND TAMPONADE AGENTS 403
Vitrectomy: heavy liquids and tamponade agents
Perfluorocarbon (“heavy”) liquids
•Indications: these may be useful in repositioning of giant retinal tears, in flattening PVR-associated retina, in floating up dislocated lens fragments or IOLs, and in assisting hemostasis.
Agents
Perfluoro-n-octane is the most commonly used agent.
Tamponade
Indications
•Simple retinal detachment: consider air or SF6/air mix.
•Complicated retinal detachment (e.g., PVR, giant retinal tear, multiple recurrences): consider C3F8/air mix or silicone oil. Overall, these are similarly effective in PVR, although silicone oil is associated with better final VA in anterior disease, requires no postoperative posturing, and allows easier intraoperative and immediate postoperative visualization.
When vitrectomy has been performed for indications other than RD, there may be no need for tamponade.
Agents
Table 12.16 Common tamponade agents
Agent |
Symbol |
Expansion |
Nonexpansile |
Duration |
|
|
|
|
if 100% |
concentration |
|
|
|
|
|
|
(mixed with air) |
|
|
|
|
|
|
|
|
|
|
Air |
Air |
None |
100% |
1 week |
|
|
|
||||||
Sulfur hexafluoride |
SF6 |
x2 |
20% |
1–2 weeks |
|
|
|
||||||
Perfluoropropane |
C3F8 |
x4 |
12% |
8–10 weeks |
|
|
Silicone oil |
Si oil |
None |
100% |
Until removal |
|
|
|
|
|
|
|
|
|
Complications
•iIOP (may be related to overfill), posterior subcapsular “feathering” of the lens, anterior IOL movement (if pseudophakic).
Posturing
The aim of postoperative posturing by the patient is to achieve effective tamponade of the break by the gas bubble and keep the gas bubble away from the crystalline lens. Posturing should start as soon as possible (same day of surgery), for as much of each day as possible (commonly 50 min in every hour, and adopt appropriate sleeping posture), and continues for 1–2 weeks (with some variation according to tamponade agent).
The posture required will depend on the location of the retinal break but aims to move the break as superiorly as possible. Advise patient not to fly until the gas bubble has resolved.
This page intentionally left blank
.
Chapter 13 |
|
|
405 |
Medical retina |
|
|
|
Anatomy and physiology 406 |
|
|
|
Age-related macular degeneration (1) |
408 |
|
|
Age-related macular degeneration (2) |
410 |
|
|
Age-related macular degeneration (3) |
414 |
|
|
Anti-VEGF therapy 415 |
|
|
|
Photodynamic therapy (PDT) |
416 |
|
|
Diabetic eye disease: general |
418 |
|
|
Diabetic eye disease: assessment 420
Diabetic eye disease: management 423
Diabetic eye disease: screening 425
Central serous chorioretinopathy (CSCR or CSR) 426
Cystoid macular edema (CME) 429 |
|
|
||||
Degenerative myopia 431 |
|
|
|
|
||
Angioid streaks |
433 |
|
|
|
|
|
Choroidal folds |
434 |
|
|
|
|
|
Toxic retinopathies (1) |
435 |
|
|
|
||
Toxic retinopathies (2) |
437 |
|
|
|
||
Retinal vein occlusion (1) |
439 |
|
|
|||
Retinal vein occlusion (2) |
442 |
|
|
|||
Retinal artery occlusion (1) |
443 |
|
|
|||
Retinal artery occlusion (2) |
446 |
|
|
|||
Hypertensive retinopathy |
448 |
|
|
|||
Hematological disease 450 |
|
|
|
|||
Vascular anomalies 452 |
|
|
|
|
|
|
Radiation retinopathy 455 |
|
|
|
|||
Retinitis pigmentosa 456 |
|
|
|
|
||
Congenital stationary night blindness 458 |
|
|||||
Macular dystrophies (1) |
459 |
|
|
|||
Macular dystrophies (2) |
461 |
|
|
|||
Choroidal dystrophies 462 |
|
|
|
|||
Albinism 464 |
|
|
|
|
|
|
Laser procedures in diabetic eye disease |
466 |
|
||||
Intravitreal injection in retinal diseases 468 |
|
|||||
Related pages: |
|
|
|
|
|
|
ROP |
|
|
|
|
bp. 632 |
|
Macular hole |
|
|
|
|
bp. 395 |
|
Epiretinal membrane |
|
|
|
bp. 393 |
|
|
Hereditary vitreoretinal degenerations |
bp. 389 |
|
||||
